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MaOBJECTIVES This study sought to summarize all available evidence on sex differences in adverse drug reactions (ADRs)
to heart failure (HF) medication.
BACKGROUND Women are more likely to experience ADRs than men, and these reactions may negatively affect
women’s immediate and long-term health. HF in particular is associated with increased ADR risk because of the high
number of comorbidities and older age. However, little is known about ADRs in women with HF who are treated with
guideline-recommended drugs.
METHODS A systematic search of PubMed and EMBASE was performed to collect all available information on ADRs to
angiotensin-converting enzyme inhibitors, b-blockers, angiotensin II receptor blockers, mineralocorticoid receptor
antagonists, ivabradine, and digoxin in both women and men with HF.
RESULTS The search identiﬁed 155 eligible records, of which only 11 (7%) reported ADR data for women and men
separately. Sex-stratiﬁed reporting of ADRs did not increase over the last decades. Six of the 11 studies did not report sex
differences. Three studies reported a higher risk of angiotensin-converting enzyme inhibitor–related ADRs in women,
1 study showed higher digoxin-related mortality risk for women, and 1 study reported a higher risk of mineralocorticoid
receptor antagonist–related ADRs in men. No sex differences in ADRs were reported for angiotensin II receptor blockers
and b-blockers. Sex-stratiﬁed data were not available for ivabradine.
CONCLUSIONS These results underline the scarcity of ADR data stratiﬁed by sex. The study investigators call for a
change in standard scientiﬁc practice toward reporting of ADR data for women and men separately. (J Am Coll Cardiol HF
2019;7:258–66) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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ADR = adverse drug reaction
ARB = angiotensin II receptor
blocker
HF = heart failure
MRA = mineralocorticoid
receptor antagonist
QOL = quality of lifeW omen have an approximately 1.5 timeshigher risk of developing adverse drugreactions (ADRs) than men (1,2). They
are not only at a higher risk of hospitalization
because of the severity of their ADRs but are also
more likely to discontinue their treatment and
thereby lose its potential beneﬁt (1–4). A precise
assessment of sex-speciﬁc ADRs is complicated by
the rare reporting of such events in younger, pre-
dominantly male clinical trial groups with few
comorbidities (5–7), as well as the lack of women in
phase I clinical trials that collect data on tolerability
and dose-related ADRs (8). As a result, it is unclear
which ADRs to look for during post-marketing sur-
veillance, a system that itself is also limited by
high rates of underreporting and reporting bias (9).
The lack of sex-speciﬁc ADR data is especially
pertinent in heart failure (HF) because of the high
prevalence of comorbidities (10) and polypharmacy
in these patients (11). Women with HF are less likely
to receive guideline-recommended treatment (12,13),
possibly because of an increased risk for certain
ADRs (14). Given the under-representation of women
in all phases of clinical trials, little is known about
female-speciﬁc ADRs in patients with HF who
are treated with guideline-recommended drugs. To
expand on an earlier effort evaluating sex-speciﬁc
reporting in clinical trials (15), we performed a sys-
tematic review to identify sex-speciﬁc ADRs to
guideline-recommended HF drugs.
METHODS
SEARCH STRATEGY AND SELECTION CRITERIA. We
combined search results from PubMed Medline and
the EMBASE database. Both databases were searched
on February 20, 2018 using a pre-deﬁned search
strategy consisting of both text words and MeSH
headings. The text words were limited to title and
abstract only. We used the terms female, women,
male, men, sex, gender for the sex-speciﬁc part of
the search strategy; the terms heart failure, heart
decompensation, cardiac decompensation for the HF
domain; and the terms drug-related side effects and
adverse reactions, side effect, adverse effect for
the ADR component. We speciﬁcally excluded
chemotherapy-induced HF and studies in children.
We included all ejection fractions. The search was
updated on October 18, 2018.
Guideline-recommended HF drugs were based on
the 2016 HF treatment guidelines from the European
Society of Cardiology (16). There are 5 groups of
HF drugs: angiotensin-converting enzyme (ACE)
inhibitors, beta-blockers, angiotensin II receptorblockers (ARBs), mineralocorticoid receptor
antagonists (MRAs), and ivabradine (16). We
added digoxin because of its suggested
harmful effects in women (1).
Only original research articles written in
English or Dutch were considered for inclu-
sion. Records were included if they
mentioned any sex-speciﬁc ADRs related to 1
of the recommended HF drugs. We excluded
studies with study groups too small for sex-
stratiﬁed analyses (n ¼ <50), where the pri-
mary study group was not HF speciﬁc or had
reduced left ventricular function secondary to a
recent myocardial infarction. We excluded studies
where the results could not be linked back to 1 spe-
ciﬁc drug or where the drug was administered intra-
venously. We excluded studies where the drug was
administered only once to evaluate ﬁrst-dose effects.
Finally, we excluded all studies for which the full text
could not be retrieved.
For all included studies, the population size, the
percentage of women and mean age of the study
group, the description of the ADR type(s) reported,
and the sex-speciﬁc ADR results were extracted.
Meta-analysis of the results was not possible because
of heterogeneity. The data are presented separately
for each of the 5 drug categories.
RESULTS
The search returned 9,424 unique articles, 356 of
which were eligible for full-text screening. Most of
these studies were excluded because of the lack of
sex-speciﬁc data (n ¼ 144, 40%) or because the study
design did not match our search criteria (n ¼ 96, 27%).
Of the remaining articles (n ¼ 116), 25 did not provide
ADR data, 19 were written in a different language, 13
were duplicates, and for 48 the full text could not be
located. Eleven articles met the inclusion criteria and
were included in the analyses (Figure 1). The articles
were distributed relatively equally across the 3 de-
cades in which they were published and showed no
upward trend in sex-speciﬁc ADR reporting over time
(Figure 2).
Importantly, these 11 studies comprised only 7% of
the 155 studies that reported ADR data. The 11 studies
included 153,945 individuals with a mean age of
64 years (52 to 75 years) and included on average 25%
women (13% to 49%), similar to the 144 excluded
studies (29%). Four studies (36%) reported more
ADRs in women compared with men, whereas 1 study
(9%) reported more ADRs in men. The remaining
6 studies (55%) reported no difference in ADRs be-
tween the sexes. Six studies were post hoc analyses
FIGURE 1 Overview of the Systematic Search Process
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) ﬂow diagram depicting the ﬂow of information through the
different phases of a systematic review. It shows the number of records identiﬁed in the original search, the number of records included and
excluded in the screening process, and the reasons for exclusion during the full-text screening phase.
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260from randomized clinical trials, 2 used data from
health care insurance claims databases, and the
remaining 3 used patient cohorts from HF clinics
(Table 1). The availability of sex-speciﬁc ADR data
varied across the different drug categories. Two of 7digoxin studies reported sex-speciﬁc data (28.6%),
and this decreased to 1 in 8 for ACE inhibitors (5 of
40, 12.5%) and even lower fractions for the other
drugs. Sex-speciﬁc data were unavailable for ivabra-
dine (Table 1).
FIGURE 2 Sex-Speciﬁc ADR Reporting Across the Past 4 Decades
The total number of articles that reported adverse drug reaction (ADR) data (dark gray) and the number of articles that reported sex-speciﬁc
adverse drug reaction data (light gray). The articles have been divided by decade of publication. The percentage of sex-speciﬁc adverse drug
reaction papers of all adverse drug reaction papers published that period are presented on top of the light gray bars.
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261ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.
There were 40 articles with ADR data for ACE in-
hibitors, 5 of which contained sex-speciﬁc ADR data
(Table 1). These 5 studies enrolled 137,956 patients
with a mean age of 63 years (60 to 75 years) and on
average 26% women. The BIOSTAT-CHF (Systems
BIOlogy Study to TAilored Treatment in Chronic
Heart Failure) study looked at 3 different HF drugs,
including ACE inhibitors, bringing the total number of
ACE inhibitor studies to 6 (Table 1).
Data from an American claims database showed
that the incidence of angioedema was 5.16 (3.37 to
7.92) per 1,000 person-years in women who initiated
ACE inhibitor treatment compared with 2.32 (1.48 to
3.64) per 1,000 person-years in men (17). Similarly,
2 post hoc analyses of the SOLVD (Studies Of Left
Ventricular Dysfunction) reported more ADRs in
women than in men (18,19). The difference was
especially pronounced for cough, which was almost
2.5 times more prevalent in women compared with
men (18). However, this difference was not found in
a Japanese hospital-based study, where the per-
centage of cough-related ADRs was similar between
men and women (20). A third post hoc analysis ofthe SOLVD trial showed that a similar percentage of
men and women experienced at least 1 episode of
anemia during enalapril treatment (38% vs. 41%)
(21). Similarly, a post hoc analysis of the BIOSTAT-
CHF study found no signiﬁcant difference in the
number of men and women who failed to reach the
target dose of ACE inhibitor or ARB as a result of
ADRs (25% vs. 27%) (22).
ANGIOTENSIN II RECEPTOR BLOCKERS. The search
returned 23 articles with ADR data for ARBs, of which
1 contained sex-speciﬁc ADR data (Table 1). The
BIOSTAT-CHF study also evaluated ARBs, bringing
the total number of sex-speciﬁc ARB studies to 2. A
post hoc analysis of the HEAAL (Heart failure
Endpoint evaluation of Angiotensin II Antagonist
Losartan) study, which enrolled 3,834 participants
with a mean age of 67 years and 29% women, re-
ported that there were no signiﬁcant differences in
risk of kidney impairment, hyperkalemia, or hypo-
tension between men and women treated with
losartan (23) (Table 1). As mentioned earlier, a similar
percentage of men and women failed to reach the
target dose of ARB or ACE inhibitors in the BIOSTAT-
CHF study (22).
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ACE inhibitor 40 5 (12.5) (17–21) 137,956 (27) 63 (60–75) 3 (w) 2 3 (ct), 1 (ch), 1 (cd) Cough (3), angioedema (1),
anemia (1)
ARB 23 1 (4.3) (23) 3,834 (30) 67 1 1 (ct) Kidney impairment,
hyperkalemia, hypotension
BB 45 1 (2.2) (24) 230 (13) 52 1 1 (ch) Fatal and nonfatal ADRs
Digoxin 7 2 (28.6) (25,26) 9,691 (29) 67 (65–69.5) 1 (w) 1 1 (ct), 1 (cd) Death, hospitalization
MRA 18 1 (5.6) (27) 134 (32) 66 1 (m) 1 (ch) Discontinuation of
treatment due to ADRs
Ivabradine 3 0 (0.0)
Combination
of drugs
19 1 (5.3) (22) 2,100 (25) 68 1 1 (ct) Failure to reach target
dose due to ADRs
Total 155 11 (7.1) 153,945 (26) 64 (52–75) 4 (w) / 1 (m) 6 6 (ct), 3 (ch), 2 (cd)
Values are n, n (%), or mean (interquartile range).
ACE ¼ angiotensin-converting enzyme; ADR ¼ adverse drug reaction; ARB ¼ angiotensin II receptor inhibitor; BB ¼ b-blocker; cd ¼ claims database; ch ¼ cohort; ct ¼ clinical trial; m ¼ men; MRA ¼
mineralocorticoid receptor antagonist; w ¼ women.
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262b-BLOCKERS. In total, 45 articles provided ADR data
for b-blockers, and 1 of these articles reported sex-
speciﬁc ADR data (Table 1). The BIOSTAT-CHF study
included an evaluation of b-blockers, bringing the
total number of b-blocker studies to 2. A study from
an HF clinic in Australia, which included 230 patients
with HF with a mean age of 52 years and 13% women,
reported that men and women treated with carvedilol
reported similar numbers of ADRs (12% vs. 10%,
respectively) (24). Data from the BIOSTAT-CHF study
suggest that a similar percentage of men and women
failed to reach target dose as a result of ADRs (20% vs.
22%, respectively) (22).
DIGITALIS GLYCOSIDES. There were 7 articles with
ADR data for digoxin, of which 2 evaluated the effects
of sex (Table 1). Together these 2 studies included
9,691 patients with a mean age of 67 years (65 to 70
years) and on average 28% women (Table 1). A post
hoc analysis of the DIG (Digitalis Intervention Group)
study data suggested that women treated with
digoxin had an approximately 20% higher risk of
death compared with the placebo group (hazard ratio:
1.23; 95% conﬁdence interval: 1.02 to 1.47), although
this difference was not seen for men (hazard ratio:
0.93; 95% conﬁdence interval: 0.85 to 1.02) (25).
This sex difference was not present in data from an
American claims cohort, where the risk for death and
hospitalization was similar for men and women (26).
MINERALOCORTICOID RECEPTOR ANTAGONISTS.
The search returned 18 articles with ADR data for
MRAs, 1 of which reported sex-speciﬁc ADR data
(Table 1). This study enrolled 134 patients with HF
with a mean age of 66 years and 31% women. Thepatients were followed up for discontinuation of
treatment because of hyperkalemia, deterioration of
renal function on the basis of serum creatinine, and
gynecomastia in men. These investigators found that
16% of the women treated with spironolactone with-
drew from treatment because of ADRs compared with
28% of the men (27).
IVABRADINE. In total, 3 studies provided ADR data
for ivabradine, of which none reported sex-speciﬁc
results (Table 1).
DISCUSSION
We show a general lack of information about sex-
speciﬁc ADRs for guideline-recommended HF drugs.
Of the 155 ADR records returned by the search, only 11
(7%) provided sex-speciﬁc ADR data. The majority of
these 11 studies (55%) reported no sex differences in
ADRs. Women may have more ADRs related to ACE
inhibitors and digoxin, whereas men may experience
more ADRs related to MRAs. However, the low num-
ber of studies and participants in some studies make
it difﬁcult to draw solid conclusions.
LACK OF SEX-SPECIFIC DATA. We show that the lack
of sex-speciﬁc ADR data is widespread in observa-
tional studies. Only 7% of all available studies,
spanning a large range of study group sizes and
publication years, reported sex-speciﬁc ADR results.
In line with the limited effect of efforts to increase the
participation of women in cardiovascular trials (28),
there was no upward trend in sex-speciﬁc reporting
over time. We therefore argue that sex-speciﬁc
reporting should receive attention separately from
CENTRAL ILLUSTRATION Underlying Sex Differences in
Heart Failure That Necessitate Sex-Speciﬁc Reporting














Report Adverse Drug Reactions for
Women and Men Separately
Bots, S.H. et al. J Am Coll Cardiol HF. 2019;7(3):258–66.
This ﬁgure summarizes the underlying sex differences in heart failure that support the
need to report adverse drug reactions (ADRs) for women and men separately. HFpEF ¼
heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection
fraction.
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263the proportionate representation of women, even
though these problems are connected.
Sex-speciﬁc data reporting should be regarded as
standard practice instead of a statistical power–
dependent subgroup analysis. Reporting data for
women and men separately reﬂects proper scientiﬁc
conduct to support future meta-analyses. In situa-
tions where data are scarce, even the smallest studies
can contribute, an argument also made for dementia
trials (29).
UNDER-REPRESENTATION. The persistent under-
representation of women in clinical trials (6,28,30–32)
calls for a new approach to address the lack of female-
speciﬁc data (Central Illustration). ADRs that may be
relatively common in women become too rare to be
detected in a clinical trial population with only few
women, thereby creating an evidence gap. In addi-
tion, the lack of sex-stratiﬁed data hinders the iden-
tiﬁcation of sex-speciﬁc ADR trends. Observational
studies have the unique potential to ﬁll this evidence
gap because they include more women and are thus
able to stratify their results by sex. Early-stage safety
and dose-ﬁnding trials should also be included in this
effort because they have the opportunity to detect
sex differences early on without the need to conduct
large-scale studies. Observations from these studies
can lead to interesting insights (14) that can inform
health care professionals and treatment guidelines on
optimal treatment for both sexes until sufﬁcient
clinical trials with a proportionate amount of women
and sex-stratiﬁed ADR data have been conducted.
SUSCEPTIBILITY TO ADVERSE DRUG REACTIONS.
Patients with HF often also have 5 or more comor-
bidities and take on average 10 different medications
(11,33,34). Women more often have HF with preserved
ejection fraction than men (Central Illustration), a
subtype characterized by additional comorbidities and
older age compared with other HF subtypes (10,33). In
addition, women seem to use more medications than
men (4,35). These factors increase the risk for drug-
drug interaction ADRs in women with HF, which is
indeed 1 of the 3 driving factors behind sex differences
in ADR reporting (2) (Central Illustration). The other 2
are sex differences in pharmacokinetics and pharma-
codynamics (2), of which differences in distribution
volume, hepatic and renal clearance, and sex hormones
seem to be the key players. The biological processes
underlying these differences have been discussed in
detail elsewhere (36,37).
ADHERENCE AND QUALITY OF LIFE. Interestingly,
women with HF with preserved ejection fraction
report a poorer quality of life (QOL) than men
regardless of disease severity (38,39). Women reportlower QOL as a result of worsening symptoms or
decreased physical functioning and overall health,
among others (40). This lower QOL may be induced
by ADRs directly or indirectly by poor adherence, the
latter view supported by the observations that QOL is
positively related with adherence (41) and that
women are more likely to be poor adherers (42).
However, much is still unclear about sex differences
in QOL (40), and further research is needed to eval-
uate sex-speciﬁc effects of ADRs on QOL properly.
SEX DIFFERENCES IN ADVERSE DRUG REACTIONS.
Three of the 6 ACE inhibitor articles included in our
review suggested that women were more likely to
experience ACE inhibitor–induced ADRs, whereas the
other 3 showed no sex differences. The higher inci-
dence of ACE inhibitor–induced cough in women has
been observed previously (43–45). In addition, ARBs
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: This
study suggests that women may experience different
ADRs than men when treated with the same HF drugs.
However, given the scarcity of data, this conclusion
should be interpreted with care. We hope these re-
sults will stimulate clinicians to consider the sex of
their patients when they prescribe HF drugs and that
they will report sex-speciﬁc data in their own scien-
tiﬁc work.
TRANSLATIONAL OUTLOOK: The identiﬁcation
and scientiﬁc evaluation of ADRs caused by HF med-
ications used in the clinic require large amounts of
sex-speciﬁc data, which are currently not available.
We believe that observational studies can play a large
role in ﬁlling this evidence gap. Viewing sex-stratiﬁed
reporting as an example of good scientiﬁc conduct
instead of a power-driven subgroup analysis will aid
the discovery of sex-speciﬁc ADRs to HF drugs. In
turn, this will help clinicians to make more informed
decisions when prescribing HF drugs.
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264seem to have better efﬁcacy and adherence proﬁles
than ACE inhibitors in women with congestive HF but
not in men (14). Women may thus be at higher risk
of ACE inhibitor–induced ADRs, which negatively
affects their adherence and treatment beneﬁt, but
more data are needed to draw a solid conclusion. The
small Japanese study identiﬁed by our search re-
ported no sex differences in ACE inhibitor–induced
ADRs, whereas other studies suggest these ADRs to
be more prevalent among Asian populations (46,47).
This ﬁnding may be explained by the small study size
in combination with the small number of reported
ADRs (n ¼ 37, 19 women), or the sex difference may be
masked by the higher ADR prevalence. Regarding
angioedema the results are less clear, with some
previous studies showing a higher incidence in
women (48) and others showing no sex differences
(49). Additional data on angioedema may lead to
more insight into this matter.
We did not ﬁnd evidence for sex differences in
ADRs for ARBs and b-blockers. Our results on digoxin
are contradictory because the higher risk of hospi-
talization and death in women related to digoxin
treatment observed in a post hoc analysis from the
DIG trial was not observed in a large cohort. Similarly,
data from a British cohort study did not observe any
sex differences in the risk of all-cause mortality in
patients treated with digoxin (50), and there is some
evidence that digoxin is equally beneﬁcial in both
men and women at low blood concentrations (51).
Scientiﬁc evidence claiming no sex differences may
outweigh the evidence that suggests the presence of
sex differences in digoxin-related ADRs. More data
are needed to support this claim.
The only MRA article returned by our search
showed a higher number of spironolactone-related
ADRs in men than women. Spironolactone is known
to induce gynecomastia (52) and hyperkalemia, which
occur more frequently in men than women (53). This
could explain why men more often withdrew from
MRA treatment than women, but additional data may
shed more light on the issue.
STUDY LIMITATIONS. This systematic review com-
bines all available knowledge on sex-speciﬁc ADRs for
guideline-recommended HF drugs. Because of the
lack of data and heterogeneity of the available data,
however, the results could not be meta-analyzed. The
deﬁnition of HF was not identical across included
studies, possibly leading to some misclassiﬁcation in
individual studies. As a result, we were unable to split
our result by HF subtype. We excluded diuretic
agents and sacubitril-valsartan from our searchbecause the ﬁrst agents are used only to treat symp-
toms and the second drugs were discovered too
recently for sex-speciﬁc post hoc studies to be pub-
lished but should be included in future efforts. The
low number of returned studies obliges us to interpret
our results with care. We were unable to discuss sex-
speciﬁc ADRs for ivabradine because of the lack of
data. However, the scarcity of data in itself is an
important ﬁnding that hopefully inspires future re-
searchers to sex-stratify their results.
CONCLUSIONS
The scarcity of sex-speciﬁc ADR data for guideline-
recommended HF drugs data hampers the identiﬁ-
cation of female-speciﬁc ADRs. The currently
available evidence hints at the existence of sex-
speciﬁc ADRs but remains inconclusive given the
scarcity of data. Sex-speciﬁc ADR reporting in articles
has not increased over the past 3 decades. A call to
action is needed to incorporate sex-speciﬁc reporting
into scientiﬁc practice.
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